These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 9934343

  • 1. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
    Krahn MD, Coombs A, Levy IG.
    CMAJ; 1999 Jan 12; 160(1):49-57. PubMed ID: 9934343
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Costs and benefits of prostate cancer screening. Investigators of the American Cancer Society--National Prostate Cancer Detection Project.
    Littrup PJ, Goodman AC.
    In Vivo; 1994 Jan 12; 8(3):423-7. PubMed ID: 7803728
    [Abstract] [Full Text] [Related]

  • 9. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S, Porter M.
    BJU Int; 2009 Nov 12; 104(10):1457-61. PubMed ID: 19522868
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
    Bermúdez-Tamayo C, Martín Martín JJ, González Mdel P, Pérez Romero C.
    Urol Int; 2007 Nov 12; 79(4):336-44. PubMed ID: 18025853
    [Abstract] [Full Text] [Related]

  • 11. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
    Telesca D, Etzioni R, Gulati R.
    Biometrics; 2008 Mar 12; 64(1):10-9. PubMed ID: 17501937
    [Abstract] [Full Text] [Related]

  • 12. Future benefits and cost-effectiveness of prostate carcinoma screening. American Cancer Society.
    Littrup PJ.
    Cancer; 1997 Nov 01; 80(9):1864-70. PubMed ID: 9351561
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry.
    Stattin P, Johansson R, Damber JE, Hellström M, Hugosson J, Lundgren R, Varenhorst E, Johansson JE.
    Scand J Urol Nephrol; 2003 Nov 01; 37(6):461-5. PubMed ID: 14675917
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A.
    Prog Urol; 2009 Jul 01; 19(7):487-98. PubMed ID: 19559380
    [Abstract] [Full Text] [Related]

  • 18. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
    Bourel M, Ardaillou R, Académie nationale de médecine.
    Bull Acad Natl Med; 2003 Jul 01; 187(5):985-95. PubMed ID: 14979060
    [Abstract] [Full Text] [Related]

  • 19. Economic evaluation of prostate cancer screening with prostate-specific antigen.
    Imamura T, Yasunaga H.
    Int J Urol; 2008 Apr 01; 15(4):285-8. PubMed ID: 18380812
    [Abstract] [Full Text] [Related]

  • 20. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ, Roobol DW, Schröder FH.
    Urology; 2005 Feb 01; 65(2):343-6. PubMed ID: 15708050
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.